129 related articles for article (PubMed ID: 35016891)
1. SOX9 and SATB2 immunohistochemistry cannot reliably distinguish between osteosarcoma and chondrosarcoma on biopsy material.
Sharma AE; Pytel P; Cipriani NA
Hum Pathol; 2022 Mar; 121():56-64. PubMed ID: 35016891
[TBL] [Abstract][Full Text] [Related]
2. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
3. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].
Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893
[TBL] [Abstract][Full Text] [Related]
4. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
Davis JL; Horvai AE
Histopathology; 2016 Jul; 69(1):84-90. PubMed ID: 26644288
[TBL] [Abstract][Full Text] [Related]
5. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
6. SATB2 is not a reliable diagnostic marker for distinguishing between oral osteosarcoma and fibro-osseous lesions of the jaws.
Grad-Akrish S; Rachmiel A; Ben-Izhak O
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 May; 131(5):572-581. PubMed ID: 33309262
[TBL] [Abstract][Full Text] [Related]
7. Expression of SATB2, RUNX2, and SOX9 and possible osteoblastic and chondroblastic differentiation in chondroblastoma.
Toda Y; Yamamoto H; Iwasaki T; Ishihara S; Ito Y; Susuki Y; Kawaguchi K; Kinoshita I; Kiyozawa D; Yamada Y; Kohashi K; Kimura A; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
Pathol Res Pract; 2023 Jan; 241():154239. PubMed ID: 36442415
[TBL] [Abstract][Full Text] [Related]
8. [Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma].
Chen CY; Zhang HZ; Jiang ZM; Zhou J; Chen J; Liu L
Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):387-92. PubMed ID: 27256046
[TBL] [Abstract][Full Text] [Related]
9. Expression of SATB2 in primary cutaneous sarcomatoid neoplasms: a potential diagnostic pitfall.
Szczepanski JM; Siddiqui J; Patel RM; Harms PW; Hrycaj SM; Chan MP
Pathology; 2023 Apr; 55(3):350-354. PubMed ID: 36732203
[TBL] [Abstract][Full Text] [Related]
10. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours.
Conner JR; Hornick JL
Histopathology; 2013 Jul; 63(1):36-49. PubMed ID: 23701429
[TBL] [Abstract][Full Text] [Related]
11. SATB2 Immunopositivity in Spindle Cell (Sarcomatoid) Squamous Cell Carcinoma: A Potential Pitfall in Diagnosis.
Sasidharan A; Kakkar A; Thakar A; Deo SVS
Appl Immunohistochem Mol Morphol; 2022 Mar; 30(3):184-189. PubMed ID: 35262524
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, Sox9, and osteocalcin immunostaining of 22 cases.
Fanburg-Smith JC; Auerbach A; Marwaha JS; Wang Z; Rushing EJ
Hum Pathol; 2010 May; 41(5):653-62. PubMed ID: 20138330
[TBL] [Abstract][Full Text] [Related]
13. Periosteal osteosarcoma and parosteal chondrosarcoma evaluated by double immunohistochemical staining. Report of 2 cases.
Chano T; Matsumoto K; Ishizawa M; Morimoto S; Hukuda S; Okabe H
Acta Orthop Scand; 1994 Jun; 65(3):355-8. PubMed ID: 7518993
[TBL] [Abstract][Full Text] [Related]
14. SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors.
Dum D; Kromm D; Lennartz M; De Wispelaere N; Büscheck F; Luebke AM; Burandt E; Menz A; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Lebok P; Sauter G; Simon R; Uhlig R; Wilczak W; Minner S; Krech R; Bernreuther C; Marx A; Steurer S; Jacobsen F; Clauditz T; Krech T
Arch Pathol Lab Med; 2023 Apr; 147(4):451-464. PubMed ID: 35917493
[TBL] [Abstract][Full Text] [Related]
15. Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series.
Wojcik JB; Bellizzi AM; Dal Cin P; Bredella MA; Fletcher CD; Hornicek FJ; Deshpande V; Hornick JL; Nielsen GP
Am J Surg Pathol; 2014 Nov; 38(11):1538-44. PubMed ID: 24921641
[TBL] [Abstract][Full Text] [Related]
16. NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study.
Syed M; Mushtaq S; Loya A; Hassan U
Ann Diagn Pathol; 2021 Feb; 50():151660. PubMed ID: 33302222
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Osteoblastic Osteosarcoma: Report of 2 New Cases Integrated With SATB2 Immunohistochemistry and Review of the Literature.
Falconieri G; Cataldi P; Kavalar R; Štitič V; Luzar B
Am J Dermatopathol; 2016 Nov; 38(11):824-831. PubMed ID: 27043339
[TBL] [Abstract][Full Text] [Related]
18. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma.
Ordóñez NG
Adv Anat Pathol; 2014 Jan; 21(1):63-7. PubMed ID: 24316906
[TBL] [Abstract][Full Text] [Related]
19. Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling.
Xu HY; Fang W; Huang ZW; Lu JC; Wang YQ; Tang QL; Song GH; Kang Y; Zhu XJ; Zou CY; Yang HL; Shen JN; Wang J
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4516-4528. PubMed ID: 29131265
[TBL] [Abstract][Full Text] [Related]
20. cFOS-SOX9 Axis Reprograms Bone Marrow-Derived Mesenchymal Stem Cells into Chondroblastic Osteosarcoma.
He Y; Zhu W; Shin MH; Gary J; Liu C; Dubois W; Hoover SB; Jiang S; Marrogi E; Mock B; Simpson RM; Huang J
Stem Cell Reports; 2017 Jun; 8(6):1630-1644. PubMed ID: 28552607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]